Sintilimab and Chidamide for Refractory Transformed Diffuse Large B Cell Lymphoma: A Case Report and A Literature Review
Patients with relapsed/refractory (R/R) transformed diffused large B cell lymphoma (tDLBCL) have a poor prognosis and a low survival rate. In addition, no standard therapy has yet been established for R/R tDLBCL. Herein we presented a single case of a patient with R/R tDLBCL who was successfully tre...
Guardado en:
Autores principales: | Chao Chen, Wei Zhang, Daobin Zhou, Yan Zhang |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/9a18cc86773d4bb3be23905569fb2808 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Preclinical Evaluation of the HDAC Inhibitor Chidamide in Transformed Follicular Lymphoma
por: Mengya Zhong, et al.
Publicado: (2021) -
Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience
por: Schaefer A, et al.
Publicado: (2021) -
Absolute monocyte count as a prognostic parameter in diffuse large B cell lymphoma
por: IRIGOÍN,VICTORIA, et al.
Publicado: (2019) -
Epstein-Barr Virus-Positive Adrenal Diffuse Large B-Cell Lymphoma after Treatment for Angioimmunoblastic T-Cell Lymphoma
por: Akiko Hashimoto, et al.
Publicado: (2021) -
Primary diffuse large B-cell lymphoma of the prostate: a case report and review of the literature
por: Mengwei Ren, et al.
Publicado: (2021)